Clinical Trial Product Liability Insurance is a crucial safeguard for life sciences companies conducting human clinical trials. It provides coverage for bodily injury or property damage arising from a product being tested, as long as trial protocols are followed and policies’ specific terms are met.National Academies.
These coverages typically come in the form of:
- Master policies—renewed annually and covering all trials under your organization.
- Local policies—for trials conducted in foreign jurisdictions.
Policy structures often include strict claim reporting provisions and require extended reporting periods or “run-off” coverage if your organization is acquired or ceases operations.
Key Coverage Highlights
- Master policies for Phase I and II trials frequently carry limits of around $5 million, while Phase III trials may go up to $10 million.
- “No-fault” medical expense coverage, ensuring compensation regardless of negligence.
- Protection for both sponsors and related entities, such as contract research organizations (CROs) and institutional review boards (IRBs), when trial protocols are followed.
- Strong emphasis on navigating gaps in coverage, since clinical trials liability is highly specialized and not a substitute for general or product liability policies.
Why It Matters
Clinical trial liability coverage is more than a regulatory check-box—it’s a risk management essential. Trials involve human subjects, and unforeseen claims—even years post-trial—can arise. Comprehensive policies with sufficient limits and extended reporting ensure that companies remain protected long after the trial concludes.
Even if you work with multiple insurers, consolidating product liability and clinical trial coverage with a single provider can help avoid coverage gaps and streamline claims handling.